Thus, Rac may drive both the AKT/mTOR and MEK/ERK pathways only in select subtypes of cancer cells, making Rac a promising therapeutic target that could supplant that need for drug combinations targeting individual components of both the PI3K/AKT/mTOR and MEK/ERK pathways. Here, MAP2K7 is linked to cancer.